Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SwallPEG: Prophylactic vs Reactive PEG in Oropharyngeal Cancer
NCT04019548Phase 3Recruiting
- Sponsor
- Institut Jules Bordet
- Start
- Dec 2019
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Institut Jules Bordet. Primary endpoint: M.D. Anderson Dysphagia Inventory. Started Dec 2019; status: recruiting.
Beyond the preview
Go deeper on NCT04019548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019548.